<DOC>
	<DOCNO>NCT02626338</DOCNO>
	<brief_summary>The propose study design combine crenolanib standard salvage chemotherapy treat patient R/R AML irrespective FLT3 status .</brief_summary>
	<brief_title>Pilot Study Crenolanib Combined With Standard Salvage Chemotherapy Subjects With R/R AML</brief_title>
	<detailed_description>Open label , dose de-escalation , phase 1b pilot trial crenolanib standard salvage chemotherapy . Subjects may receive 2 cycle induction standard salvage chemotherapy follow crenolanib . Each arm enroll approximately 24 patient ( 72 total ) ; stratification arm per physician 's choice</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Crenolanib</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Confirmed diagnosis AML , include treatmentrelated secondary AML ( except prior MDS ) accord World Health Organization ( WHO ) 2008 classification treat institution 2 . Subjects refractory* relapsed** follow first line AML therapy cytarabine/anthracycline base chemotherapy , without tyrosine kinase inhibitor . *Refractory induction therapy define never achieve CR , CRi CRp ( accord International Working Group criterion ) one line intensive regimen AML ( reinduction , consolidation and/or transplant allow ) include least one cytarabine contain induction block total dose le 700mg/m² per cycle 3 day anthracycline without TKI . **First relapse define untreated hematologic relapse ( accord International Working Group criterion ) one line intensive regimen AML ( reinduction , consolidation and/or transplant allow ) include least one cytarabine contain induction block total dose le 700mg/m² per cycle 3 day anthracycline without TKI induce CR/CRi/CRp . Subjects allow receive induction , consolidation , transplant and/or maintenance prior achieve first CR/CRi/CRp . 3 . Subjects consider eligible intensive chemotherapy 4 . ECOG performance status ≤ 2 5 . Age ≥ 18 year 6 . Adequate liver function within 72 hour enrollment , define : Normal total serum bilirubin ALT AST ≤ 2.0 x ULN 7 . Adequate renal function , define serum creatinine ≤ 1.5x ULN 8 . Women childbearing potential must negative serum urine pregnancy test sensitivity least 25 mIU/mL within 72 hour prior enrollment `` Woman childbearing potential '' define woman undergone hysterectomy menses time precede 24 consecutive month 9 . Women childbearing potential must either commit continued abstinence heterosexual intercourse begin one acceptable method birth control ( IUD , tubal ligation , partner 's vasectomy ) crenolanib 3 month follow last dose crenolanib . Hormonal contraception alone acceptable method birth control purpose trial . 10 . Men must use latex condom sexual contact woman childbearing potential , even undergone successful vasectomy must agree avoid father child ( therapy 3 month last dose crenolanib ) . 11 . Willing adhere protocol specific requirement 12 . Following receipt verbal write information study , subject must provide sign informed consent study related activity carry . 13 . Clinically significant toxic effect prior therapy ( expect hydroxyuria ) resolve Grade ≤ 1 start study . Exclusion Criteria 1 . &lt; 5 % blast blood marrow screening , except measurable extramedullary AML confirm 2 . Acute promyelocytic leukemia ( APL ) 3 . Known clinically active CNS leukemia 4 . Clinically active unstable graftversushost disease ( GvHD ) require treatment precludes administration chemotherapy define protocol 5 . Prior antileukemia therapy within 14 day enrollment classical cytotoxic agent , within 5x halflife investigational agent Prior use hydroxyurea isolated dos cytarabine palliation ( i.e. , control WBC ) allow discontinue least 24 hrs prior enrollment . Other agent use strictly palliative intent might allow period discuss principal investigator 6 . Preexisting liver disease ( e.g . cirrhosis , chronic hepatitis B C , nonalcoholic steatohepatitis , sclerosing cholangitis ) 7 . Known HIV infection . 8 . Evidence ongoing , uncontrolled systemic infection uncontrolled local infection require therapy start study . 9 . `` Currently active '' second malignancy ( nonmelanoma skin cancer , carcinoma situ cervix prostatic intraepithelial neoplasia within 1 year ) . Subjects consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse within 1 year . 10 . Concurrent participation another therapeutic clinical trial . 11 . Pregnant breastfeed woman 12 . Subjects childbearing potential willing use adequate contraception study 3 month last dose crenolanib 13 . Subject uncontrolled cardiac disease include congestive heart failure class III IV NYHA , unstable angina ( anginal symptom rest ) new onset angina ( begin within last 3 month ) myocardial infarction within past 6 month 14 . Subject concurrent severe and/or uncontrolled medical psychiatric condition opinion investigator may impair participation study evaluation safety and/or efficacy 15 . Inability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>